- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01268709
Effect of Doxepin and Nortriptyline on Irritable Bowel Syndrome
December 30, 2010 updated by: Qom University of Medical Sciences
The objective of this randomized triple blind controlled trial is to compare the effects of Doxepin and Nortriptyline on diarrhea predominant irritable bowel syndrome.
In this stuy, 75 patients with IBS are randomly assigned to receive Doxepin , Nortriptyline or placebo, a tablet per day, orally, for two months.
Abdominal pain, mucus in the stool, incomplete evacuation, and bloating are measured and compared between groups at the baseline and one and two month after the intervention.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Qom, Iran, Islamic Republic of, 1677859642
- Gastrointestinal Research center,Beheshti Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Presence of diarrhea predominant irritable bowel syndrome according to ROME criteria
Exclusion Criteria:
- Gastrointestinal bleeding
- More than 5% weight loss in the last 6 months
- Presence of any finding in favor of organic disorders in the lab tests or organic disorder in colonoscopy of high risk patients
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: placebo
|
|
|
Active Comparator: doxepin
|
|
|
Active Comparator: nortriptyline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
December 30, 2010
First Submitted That Met QC Criteria
December 30, 2010
First Posted (Estimate)
December 31, 2010
Study Record Updates
Last Update Posted (Estimate)
December 31, 2010
Last Update Submitted That Met QC Criteria
December 30, 2010
Last Verified
December 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Disease
- Gastrointestinal Diseases
- Colonic Diseases, Functional
- Colonic Diseases
- Intestinal Diseases
- Syndrome
- Irritable Bowel Syndrome
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Hypnotics and Sedatives
- Antidepressive Agents, Tricyclic
- Sleep Aids, Pharmaceutical
- Histamine Antagonists
- Histamine Agents
- Adrenergic Uptake Inhibitors
- Nortriptyline
- Doxepin
Other Study ID Numbers
- YRC-1246
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.